Form 4: Revance Therapeutics CLO & GC, Dwight Moxie, Reports Beneficial Ownership Changes Following Merger

Dwight Moxie, CLO & GC of Revance Therapeutics, reports changes in beneficial ownership due to the merger with Crown Laboratories, including the tendering of shares and cancellation of restricted stock units and performance-based restricted stock units.

Summary

• Dwight Moxie, the Chief Legal Officer & General Counsel of Revance Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• These changes are a result of the merger agreement between Revance Therapeutics and Crown Laboratories, where Crown Laboratories acquired Revance.
• Moxie tendered 47,815 shares of common stock at $3.65 per share as part of the merger.
• Outstanding and unvested restricted stock units (RSUs) were canceled and converted into the right to receive cash based on the merger price of $3.65 per share.
• Performance-based restricted stock units (PSUs) were also canceled and converted into the right to receive a lump sum cash payment based on the merger price and achievement of performance metrics as defined in the merger agreement.
• Moxie now directly owns 18,125 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The merger provides liquidity to shareholders, but it also means the end of Revance Therapeutics as an independent entity. The score reflects the completion of a significant corporate event.

Positives

• The merger provides liquidity to shareholders through the cash tender offer.

Future Outlook

The merger between Revance Therapeutics and Crown Laboratories is complete, and Revance Therapeutics is now a wholly-owned subsidiary of Crown Laboratories.

Industry Context

The acquisition of Revance Therapeutics by Crown Laboratories reflects ongoing consolidation trends in the biotechnology and aesthetics industry, where larger companies acquire smaller firms with promising technologies or products.

Comparison to Industry Standards

• Mergers and acquisitions are common in the biotech industry, with valuations often based on the target company's pipeline, technology, and market potential.
• Comparable transactions in the aesthetics space include Allergan's acquisition of Zeltiq Aesthetics and Galderma's acquisition of Q-Med.
• The $3.65 per share price reflects the negotiated value based on Revance's assets and future prospects.

Stakeholder Impact

• Shareholders received cash for their shares.
• Employees may experience changes as a result of the merger.
• The merger could lead to changes in the availability and development of Revance's products.

Key Dates

Keywords

Form 4, beneficial ownership, Revance Therapeutics, Crown Laboratories, merger, Dwight Moxie, RVNC, tender offer, RSU, PSU